The 2026 minimum-credible diagnostic

For the reader paying somewhere between €2,000 and €17,000 for a longevity diagnostic day, the practical question is: what should be in this workup, and how do I know if mine is missing something it shouldn’t be missing?

Five years of practice and the prior decade of cardiometabolic literature have settled most of this question. Below is what we believe a credible 2026 longevity diagnostic should produce. We use this list internally when scoring clinics on the diagnostic depth axis.

Imaging

Whole-body MRI on a 3T magnet. Non-negotiable for the upper-tier clinic. The 3T magnet matters: the resolution gap between 1.5T and 3T is the difference between a screening tool and a clinically useful one. Reading should be by a credentialled radiologist, with AI augmentation as an aid rather than a replacement.

Cardiac assessment. At minimum, a coronary calcium score by CT. Better, for patients with risk factors, a coronary CT angiography. Cardiac MRI is appropriate for specific indications. An echocardiogram, if functional concern.

Brain imaging is appropriate in the upper tier, especially for the patient with cognitive complaints, family history of dementia, or specific risk factors. We are sceptical of routine brain MRI in asymptomatic adults under fifty.

What we deduct points for the absence of: any kind of imaging at all.

Bloodwork

A 200+ marker panel is the upper-tier bar. We don’t need to be doctrinaire about the exact count, but the panel must include:

• Comprehensive lipid panel including ApoB and Lp(a) (these matter; routine cholesterol panels miss the load-bearing markers)
• Insulin sensitivity markers — fasting insulin, HOMA-IR
• Inflammation — high-sensitivity CRP at minimum, ideally also IL-6, fibrinogen
• Hormonal depth — testosterone, free testosterone, SHBG, oestradiol, DHEA-S, IGF-1, full thyroid panel
• Iron studies including ferritin and transferrin saturation
• Comprehensive metabolic panel
• Vitamin D, B12, folate, vitamin A

A 100+ marker panel is the floor. Below this you are buying a partial workup.

What we deduct points for: hormone panels with only total testosterone, or lipid panels without ApoB.

Functional testing

CPET-grade VO₂ max — cardiopulmonary exercise testing with breath-by-breath gas analysis, lactate threshold, ventilatory thresholds. The treadmill metabolic cart at the upper-tier gym is not a CPET. The gap matters: VO₂ max is the strongest single predictor of all-cause mortality we currently have, and the precision of the test affects the action it justifies.

DEXA composition. Not just total body fat — segmental analysis, visceral adipose, lean mass distribution. Trended year-over-year, this is the single most useful body composition tool.

Continuous glucose monitor, minimum fourteen days, ideally extending into a structured nutritional challenge. The information density of a two-week CGM is enormous and the cost is trivial.

What we deduct points for: a treadmill VO₂ measurement reported as CPET, or DEXA without segmental analysis.

What’s optional but valuable

Genome sequencing. Whole-genome, not a SNP chip. The clinical actionability is real but currently sparse — a handful of pharmacogenomic decisions, family-cancer-risk decisions for those with relevant histories, ApoE for cognitive-decline risk stratification. Useful at the upper tier, particularly for patients with significant family history. Not a standalone workup justification for an asymptomatic thirty-five-year-old.

Multi-cancer early detection panel. Galleri and equivalents — a methylation-based liquid biopsy panel that screens for fifty-plus cancer types. Positive predictive value sits in the 38–43% range in published data, meaning a meaningful share of positives turn out to be benign. Useful as part of a layered workup with appropriate clinical communication; problematic when sold without clear false-positive context.

Microbiome stool analysis. Genuinely interesting science, modest current clinical actionability. Includes in upper-tier programmes; we don’t credit a great deal for it but we don’t deduct.

Biological age clocks. Epigenetic age via Horvath, GrimAge, or PhenoAge, plus newer composite clocks like OMICm Age. Includes for the patient interested in tracking; not yet sufficient evidence to drive treatment decisions on. Should be labelled as exploratory.

What we are sceptical of

Routine PET imaging in asymptomatic patients. PET is a remarkable tool for staging known cancers and for specific neurological indications. As a screening tool in asymptomatic adults, the false-positive cost and radiation dose are not justified by the evidence currently available. Clinics that include routine PET in the screening package are over-imaging, in our view.

Heavy-metals testing without clinical indication. Mercury, lead, cadmium — meaningful when there is exposure history. Routinely included for the worried-well, mostly noise, occasionally generates expensive chelation protocols downstream that we have specific reservations about.

Hair mineral analysis, food sensitivity panels, “leaky gut” markers. Evidence-light territory. We deduct points when these appear in upper-tier diagnostic spreads.

A worked example

A credible 2026 outpatient longevity day, in our editorial view, looks roughly like this:

• Whole-body MRI on a 3T magnet with credentialled radiologist read
• Coronary calcium score (and coronary CT angiography for higher-risk patients)
• 200+ marker bloodwork including ApoB, Lp(a), comprehensive hormonal and inflammatory depth
• CPET-grade VO₂ max with lactate threshold
• DEXA with segmental analysis
• 14-day CGM, ideally with a structured nutritional protocol
• Multi-cancer early detection liquid biopsy with appropriate clinical communication
• Optional: whole-genome sequencing, microbiome, epigenetic age clocks (with experimental labelling)

The clinics in our directory that score in the 22+ range on the diagnostic depth axis — YEARS, Biograph, Human Longevity Inc., Hirslanden, Fountain Life — all run something close to this list. Not perfect overlap; close enough that the gap is editorial preference, not material.

The clinics scoring below 18 on this axis are missing meaningful items from this list. Buying a workup at one of those is buying less than the headline price suggests.

The bottom line

A credible 2026 longevity diagnostic costs in the €4,000–17,000 range and includes the items above. If your clinic charges €8,000 for a workup and isn’t running the 3T MRI plus CPET-grade VO₂ plus 200+ markers including ApoB, the workup is incomplete. You are entitled to ask why.

Don’t read the price first. Read the menu. Then read the price.